{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T16:27:41Z","timestamp":1789921661603,"version":"4.0.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>We review the implications of the recently approved aducanumab amyloid-\u03b2 immunotherapy for treating Alzheimer disease with comorbid cerebral amyloid angiopathy. In clinical trials, amyloid-\u03b2 immunotherapy has been associated with a high rate of amyloid-related imaging abnormalities, potentially driven by coexisting cerebral amyloid angiopathy. Therefore, immunotherapy\u2019s efficacy in patients may be modified by coexisting cerebrovascular pathology. We discuss the contributions of cerebral amyloid angiopathy on the development of amyloid-related imaging abnormalities and propose strategies to identify cerebral amyloid angiopathy in patients considered for immunotherapy.<\/jats:p>","DOI":"10.1161\/strokeaha.121.036873","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T05:00:43Z","timestamp":1639544443000},"page":"298-302","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":61,"title":["Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab"],"prefix":"10.1161","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8015-7929","authenticated-orcid":true,"given":"Lukas","family":"Sveikata","sequence":"first","affiliation":[{"name":"J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston (L.S., A.C., A.V.)."},{"name":"Department of Clinical Neurosciences, Division of Neurology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Switzerland (L.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Charidimou","sequence":"additional","affiliation":[{"name":"J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston (L.S., A.C., A.V.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5398-1816","authenticated-orcid":true,"given":"Anand","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston (L.S., A.C., A.V.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","unstructured":"US Food and Drug Administration (FDA). FDA\u2019s Decision to Approve New Treatment for Alzheimer\u2019s Disease. FDA [Internet]. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fdas-decision-approve-newtreatment-alzheimers-disease."},{"key":"e_1_3_3_3_2","unstructured":"Haeberlein SB Hehn C von Tian Y Chalkias S Muralidharan KK Chen T Wu S Li J Skordos L Nisenbaum Let al. EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer\u2019s Disease [Internet]. 2019 [cited 2021 Jun 9]; Available from: https:\/\/investors.biogen.com\/static-files\/8e58afa4-ba37-4250-9a78-2ecfb63b1dcb"},{"key":"e_1_3_3_4_2","unstructured":"Biogen. Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer\u2019s Disease. Biogen [Internet]. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-eisai-discontinuephase-3-engage-and-emerge-trials."},{"key":"e_1_3_3_5_2","unstructured":"Food and Drug Administration. Aduhelm. Highlights of Prescribing Information [Internet]. 2021 [cited 2021 Sep 1];Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761178s003lbl.pdf"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00213-1"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22516"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0281-2"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.18.2.311"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.46.6.1592"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000073623.84147.a8"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm840"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2004.tb00493.x"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10810"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304839"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0318-y"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2015.08.008"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007818"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2351"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003281"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.016990"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.04.009"},{"key":"e_1_3_3_24_2","unstructured":"Clinicaltrials.gov. 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer\u2019s Disease. Clinicaltrials.gov [Internet]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02477800."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/1747493019855888"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/STROKEAHA.121.036873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:21:16Z","timestamp":1715599276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/STROKEAHA.121.036873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1161\/STROKEAHA.121.036873"],"URL":"https:\/\/doi.org\/10.1161\/strokeaha.121.036873","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2021-12-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}